PMID

Data

Article Title

Organization

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

Merck Research Laboratories

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Pfizer

Prediction of Thorough QT study results using action potential simulations based on ion channel screens.

University of Oxford

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Vanderbilt University Medical Center

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

TBA

Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.

Abbott Laboratories

Synthesis and activity of novel and selective I(Ks)-channel blockers.

Aventis Pharma Deutschland

Development of Chemical Entities Endowed with Potent Fast-Killing Properties against

Glaxosmithkline

Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid)

Sage Therapeutics